| Date | Title | Description |
| 30.08.2025 | PainTEQ: Funding Raised To Advance Minimally Invasive SI Joint Solutions | PainTEQ, a leading developer of minimally invasive treatments for sacroiliac (SI) joint dysfunction, announced a majority growth recapitalization co-led by Signet Healthcare Partners and Windham Capital Partners, two U.S.-based healthcare i... |
| 10.01.2024 |
Nevro announces layoffs | Pain-treatment device company Nevro (NYSE:NVRO) announced that it is letting go of 63 employees, about 5% of its workforce, as part of a restructuring effort.
“This restructuring supports our strategy and allows us to focus our investments ... |
| 16.08.2023 |
2-year data shows painful diabetic neuropathy relief with Nevro spinal cord stimulation | Nevro (NYSE:NVRO) today announced 24-month data from its Senza painful diabetic neuropathy (PDN) spinal cord stimulation (SCS) trial.
Redwood City, California-based Nevro published its study results in Diabetes Research and Clinical Practic... |
| 19.04.2023 | Nevro Names Kevin Thornal as New Chief Executive Officer and President | D. Keith Grossman to be Appointed as Executive Chairman
Company Announces Preliminary, Unaudited Worldwide Revenue for First Quarter of 2023 of $96.3 Million and Reaffirms Full-Year 2023 Revenue and Non-GAAP Adjusted EBITDA Guidance
REDWOOD... |
| 07.03.2023 |
Nevro fully launches HFX iQ spinal cord stimulation | The HFX iQ SCS system. [Image courtesy of Nevro]Nevro (NYSE:NVRO) announced today that it initiated the full U.S. market launch for its HFX iQ spinal cord stimulation (SCS) system.
Redwood City, California–based Nevro designed HFX iQ for tr... |
| 13.10.2022 | Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain | Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response
REDWOOD CITY, Calif., Oct. 12, 2022 /PRNewswire/ -- Nevro Corp. NVRO, a glo... |
| 13.10.2022 |
FDA approves Nevro HFX iQ spinal cord stimulation | Senza HFX iQ spinal cord stimulation (SCS) system [Image from Nevro]Nevro (NYSE:NVR) announced that the FDA approved its Senza HFX iQ spinal cord stimulation (SCS) system.
Redwood City, California-based Nevro designed Senza HFX iQ to use ar... |
| 11.02.2022 | Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine | REDWOOD CITY, Calif., Feb. 11, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced 12-month data from th... |
| 25.01.2022 | Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results | REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will... |
| 10.01.2022 | Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue | REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unau... |
| 04.01.2022 | Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy | REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that UnitedHealthcare,... |
| 22.12.2021 | Nevro Announces Settlement of IP Litigation with Nalu Medical | REDWOOD CITY, Calif., Dec. 21, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent... |
| 30.11.2021 | Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting | REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations... |
| 29.11.2021 | Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy | REDWOOD CITY, Calif., Nov. 29, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced three important clinical... |
| 09.11.2021 | Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance | REDWOOD CITY, Calif., Nov. 8, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for ... |
| 02.11.2021 | Nevro Announces Update in Patent Litigation with Boston Scientific | REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found th... |
| 11.10.2021 | Nevro : to Report Third Quarter 2021 Financial Results | REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will re... |
| 31.08.2021 | Nevro : Announces Director Appointment | REDWOOD CITY, Calif., Aug. 31, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that Sri Kosaraju has been a... |
| 31.08.2021 | Nevro Announces Director Appointment | |
| 19.07.2021 | Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) | |
| 07.07.2021 | Nevro : to Report Second Quarter 2021 Financial Results | REDWOOD CITY, Calif., July 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will rep... |
| 07.07.2021 | Nevro to Report Second Quarter 2021 Financial Results | |
| 22.06.2021 | Nevro Announces SENZA-NSRBP Clinical Data Presentation at the American Society of Interventional Pain Physicians 23rd Annual Meeting | |
| 22.06.2021 | Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions | |
| 26.04.2021 | Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro's Innovative Technologies, Advanced Therapies and End-to-End Patient Support | |
| 07.04.2021 | Nevro to Report First Quarter 2021 Financial Results | |
| 05.04.2021 | Nevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology | |
| 27.01.2021 | Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results | |
| 11.01.2021 | Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue | |
| 28.12.2020 | Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy | |
| 14.12.2020 | Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific | |
| 03.12.2020 | Nevro Announces Director Appointment | |
| 17.11.2020 | Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference | |
| 05.11.2020 | Nevro Announces Third Quarter 2020 Financial Results | |
| 22.10.2020 | Nevro to Report Third Quarter 2020 Financial Results | |
| 14.10.2019 | Top 10 VCs investing in medical device companies | They include NEA, Versant Ventures, SOSV and Innova Memphis
Healthtech is a big and broad space, so much so that there are whole subsectors that see more investments than entire industries.
Medical device companies, for example, raised $2.9... |
| 18.04.2016 | Nevro gets FDA pre-market approval for spinal cord stimulation device | It is designed to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin.
“My fellow surgeons ... |
| 14.04.2016 | Are IPOs worth the gamble? This investment panel’s answers may surprise you | Here are some takeaways (unless in quotations, insights are not a direct quote):
When and why an entrepreneur should decide between and acquisition or IPO:
Lamont: An entrepreneur needs to decide if he or she wants to continue running a com... |
| 07.03.2013 | Nevro Closes $48M Series C |
MENLO PARK, CA, Medical device company, focused on improving pain relief in patients suffering from debilitating chronic pain, today announced it has completed a $48 million Series C financing round.
>> Click here for more funding ... |
| 07.03.2013 | Funding: Nevro Corp. lands $48M in support of spinal cord stimulation tech | Menlo Park, Calif.-based Nevro Corp. raised $48 million in a Series C financing round in support of its high-frequency spinal cord stimulation technology, including investments from Covidien (NYSE:COV) Ventures and Johnson & Johnson (NY... |
| 07.03.2013 | Nevro Raises $48M in Series C Financing | Nevro Corp., a Menlo Park, Calif.-based medical device company focused on improving pain relief, raised $48m in Series C financing.
The round was led by new investor Novo Ventures, with participation from New Enterprise Associates and Covid... |
| 04.06.2012 | Boston Scientific lands FDA win for new stent lengths | Regulatory Roundup | Boston Scientific lands FDA win for new stent sizes
Boston Scientific (NYSE:BSX) touted FDA clearance for the 32 mm and 28 mm lengths of its Promus Element Plus drug-eluting stents, which the med-tech giant claims now represents the broades... |
| 20.07.2011 | Nevro Raises $58M for Anti-Pain Device | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Menlo Park, CA-based Nevro, which is developing a neuromodulation device for the treatment of chronic back and leg pain, said yesterday that it has raised $58 million in a Ser... |
| 19.07.2011 | Nevro Completes $58M Financing | Nevro Corp., a Menlo Park, California-based neuromodulation company focused on relief of chronic pain, has completed a $58m financing.
The round was led by new investor Johnson & Johnson Development Corporation (JJDC), with participatio... |
| - | Are IPOs worth the gamble? This investment panel’s answers may surprise you | At the MedCity INVEST conference this week, a panel made up of two CEOs who took their companies public and a couple of venture investors talked about the advantages and drawbacks of going public compared with a strategic acquisition. They ... |
| - | Nevro gets FDA pre-market approval for spinal cord stimulation device | Nevro Corp. has won pre-market approval from the Food and Drug Administration for its Senza spinal cord stimulation device.
The Redwood City, California-based company previously got an FDA nod in May 2015 for the device, which delivers high... |
